Literature DB >> 10892606

The classification of first episode schizophrenia: a cluster-analytical approach.

I Lastra1, J L Vázquez-Barquero, S Herrera Castanedo, M J Cuesta, M E Vázquez-Bourgon, G Dunn.   

Abstract

OBJECTIVE: This paper examines, using data from the Cantabria First Episode Schizophrenia Study, the usefulness of subdividing, using a cluster analysis technique, this schizophrenia population into subgroups with similar symptoms profiles in terms of SANS and SAPS.
METHOD: Diagnostic characteristics were determined using the Present State Examination (PSE-9) and the SANS/SAPS. Premorbid adjustment was assessed using a scale developed combining the Gittelman and Klein's Scales, and the Goldstein's scales. Social Adjustment was evaluated using the WHO-DAS. In addition clinical histories were used to assess the patients' clinical course.
RESULTS: Our schizophrenic patients could be subtyped into four categories: negative, positive non-paranoid, simple and disorganized schizophrenia. There is an absence of significant association between the majority of the variables investigated and the four-cluster model.
CONCLUSION: Even though our sample could be subtyped into different categories, the model does not show predictive power according to the 3-year follow-up data.

Entities:  

Mesh:

Year:  2000        PMID: 10892606     DOI: 10.1034/j.1600-0447.2000.102001026.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders.

Authors:  Damian Läge; Samy Egli; Michael Riedel; Anton Strauss; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-30       Impact factor: 5.270

2.  Symptom dimensions and subgroups in childhood-onset schizophrenia.

Authors:  Kirsten E S Craddock; Xueping Zhou; Siyuan Liu; Peter Gochman; Dwight Dickinson; Judith L Rapoport
Journal:  Schizophr Res       Date:  2017-11-13       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.